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Abstract
Dendritic cell (DC) derived-exosomes (Dex) are nanomeric vesicles harboring functional MHC/peptide complexes promoting
T cell-dependent tumor rejection. In the first Phase I trial using peptide-pulsed Dex, the observation of clinical regressions in
the absence of T cell responses prompted the search for alternate effector mechanisms. Mouse studies unraveled the
bioactivity of Dex on NK cells. Indeed, Dex promoted an IL-15Ra- and NKG2D-dependent NK cell proliferation and activation
respectively, resulting in anti-metastatic effects mediated by NK1.1
+ cells. In humans, Dex express functional IL-15Ra which
allow proliferation and IFNc secretion by NK cells. In contrast to immature DC, human Dex harbor NKG2D ligands on their
surface leading to a direct engagement of NKG2D and NK cell activation ex vivo. In our phase I clinical trial, we highlight the
capacity of Dex based-vaccines to restore the number and NKG2D-dependent function of NK cells in 7/14 patients.
Altogether, these data provide a mechanistic explanation on how Dex may stimulate non MHC restricted-anti-tumor
effectors and induce tumor regression in vivo.
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Introduction
A growing body of evidence shows that a variety of solid human
tumors are spontaneously infiltrated by T cells and that memory
effector T cells are associated with a favorable clinical outcome
while overwhelming regulatory T cells markedly compromise long
term survival [1–4]. This past decade paved the way to the
conceptual basis of therapeutic vaccines against cancer, whereby
the induction of tumor antigen-specific T cell immunity would
lead to tumor eradication [5,6]. The molecular characterization of
cytotoxic T cell (CTL) defined-epitopes [7–9] and the anti-tumor
effects promoted by adoptive transfer of tumor antigen-specific
CTL confirmed the role of T cell immunity in the control of
cancer growth at least in melanoma bearing patients [10,11].
Indeed, this strategy can lead to more effective clinical responses
against metastatic diseases when the adoptive transfer of tumor
infiltrating T cells (TIL) is associated to lymphodepleting or
myeloablative regimen [10,12,13]. Efficient vaccination against
established tumors have been described in a variety of mouse
tumor models, guiding clinical protocols in humans but the
numerous approaches e.g. peptides, DNA or viral vaccines have
thus far met with little success in the clinic because additional
adjuvants are needed [14,15]. The dendritic cells (DC), nature’s
adjuvants, represent essential component of any type of vaccina-
tion strategy [16,17]. Preclinical studies have shown that,
whenever tested, DC can be superior to other vaccine designs
[18]. The immunogenicity of antigens delivered on DC has now
been demonstrated in healthy human volunteers [19]. A number
of clinical trials have utilized tumor antigen-loaded DC as vaccines
in humans and some clinical and immune responses without
toxicity have been observed [20,21]. Nevertheless, the response
rate using immune vaccine averages 3 to 17% [22,23]. A difficult
task of immunotherapy protocols is the identification of immuno-
logical parameters predicting clinical benefit. While the ultimate
goal should be long term survival, such an endpoint requires large
patient enrolment and long term follow up. Therefore, there is a
need for surrogate markers predictive of clinical outcome.
However, in most vaccinated patients, even in those who displayed
tumor regression, it has been difficult to ascertain the existence of
anti-vaccine T cell responses [24–27]. Surrogate markers of
efficacy could be the detection of antigen spreading i.e. the
identification of tumor specific CTL recognizing epitopes that
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alternate effectors elicited by the vaccine could mediate tumor
destruction and subsequent CTL responses [30]. Natural killer
(NK) cell activation can be critical to link innate and cognate
immune responses [31–33]. Numerous adjuvants including DC
can prime NK cell functions in vivo [34–37]. So far, investigators
have overlooked the follow up of NK cell responses in clinical
settings of discrepancy between tumor regressions and T cell
responses.
DC derived-exosomes (Dex) have been originally shown to
eradicate tumors in a T cell- dependent and Major Histocompat-
ibility Complex (MHC)-restricted manner [38]. We demonstrated
that Dex could transfer functional MHC class I and class II/
peptide complexes to DCs leading to the priming of CD8
+ and
CD4
+ T cells respectively [39–41]. The two first clinical trials
assessing the feasibility and safety of Dex pulsed with MHC class I
and class II tumor peptides in metastatic melanoma [42] and lung
cancer patients [43] revealed that large amounts of exosomal
MHC class II molecules can be purified in good manufacturing
conditions (GMP) from autologous immature DC cultures to allow
safe and prolonged immunization with Dex. If occasional tumor
regressions were also observed in these studies, no DTH responses,
peptide dose dependent effects nor T cell responses could be
detected [42,43]. Thus, we postulated that Dex could induce anti-
tumor responses by acting on other MHC unrestricted immune
effector cells. In these Phase I trials, we reported NK cell triggering
in half of the patients following Dex vaccination [42–44].
However, the mechanisms accounting for the Dex bioactivity on
NK cells remained unclear. Here we show that Dex can directly
trigger NK cell activation in humans and mice, with a critical role
for membrane bound Natural Killer Group 2 member D
(NKG2D) ligands and IL-15Ra in this bioactivity. Moreover,
the first Phase I clinical study revealed that Dex vaccines enhanced
NK cell numbers and NKG2D-dependent functions in the
majority of patients.
Results
Mouse Dex promoted NK cell proliferation and activation
in vivo
To investigate the effects of Dex on NK cells in vivo,w e
inoculated intradermally 10 mg of exosomal proteins produced
from bone marrow-derived DC (BM-DC). Thirty six hours later,
we observed a 4–5 fold increase in the number of CD3
2NK1.1
+
NK cells in the draining lymph node (Fig. 1A). In contrast
immature DC (iDC), from which Dex were derived, or irrelevant
protein pellets (cell debris) obtained during Dex purification, failed
to induce a rise in NK cell number (Fig. 1A). To assign the Dex-
mediated NK cell accumulation to recruitment or active
proliferation, we injected bromodeoxyuridine (BrdU) after Dex
administration in vivo. BrdU was significantly and selectively
incorporated in NK cells supporting the proliferative role of Dex
on NK cells (Fig. 1B, left panel). Neither CD3
+ T cells (Fig. 1B
right panel) nor B cells (not shown) entered cellular division
following Dex administration.
IL-2 and trans-presentation of IL-15 by IL-15Ra is required for
NK cell survival, homeostasis and proliferation [45,46,47].
Consequently, we investigated the role of IL-15Ra and IL-2 in
the Dex-mediated NK cell proliferation in vivo. As shown in
Figure 1B, anti-IL-15Ra neutralizing mAb abolished NK cell
proliferation (measured by BrdU incorporation) in the draining
lymph node while isotype matched control antibodies failed to do
so. Blocking IL-2 did not induce any change in the capacity of Dex
to induce NK cell proliferation and activation (data not shown).
Administration of Dex not only induced NK cell proliferation
but also activation, since NK cells up-regulated the CD69
activation marker in the draining lymph node (Fig. 2A). It is
interesting to note that immature DC or cellular debris obtained
during Dex purification failed to induce significant CD69
expression on NK cells (Fig. 2A). Moreover, NK cell cytotoxic
activity was also triggered by Dex administration (Fig. 2B). The
lytic activity against YAC-1 cells of splenocytes harvested from
mice which received 8 weekly injections of Dex was markedly
enhanced compared to controls receiving PBS (Fig. 2B). Conse-
quently, a curative injection of Dex (at day 5) could significantly
reduce the number of lung metastases in an NK1.1-dependent
manner (Fig. 2C). These data clearly indicate that Dex can
mediate NK cell activation in vivo.
NK cell triggering results from a balance between activating and
inhibitory signals. Natural Killer Group 2 member D (NKG2D) is
an activating receptor whose aberrant loss in cancer induces
immune evasion [48]. NKG2D expressed by NK cells, CD8
+
TCR (T cell receptor) ab and cdT cells can overcome the
inhibition imparted by MHC class I-specific inhibitory receptors
[49]. In NK cells, NKG2D serves as a primary activation receptor,
which by itself triggers cytotoxicity [50]. We investigated the role
of NKG2D ligands in Dex-mediated NK cell activation by
monitoring the numbers and activation status of NK cells in the
draining lymph node in the presence of Dex and neutralizing anti-
mouse NKG2D mAb. Although the accumulation of NK cells was
not affected by NKG2D blockade (Fig. 2D, left panel), the
numbers of CD3
2NK1.1
+ expressing CD69
+ significantly
dropped in the presence of anti-NKG2D mAb (Fig. 2D, right
panel).
Altogether, Dex trigger an IL-15Ra and a NKG2D-dependent
NK cell proliferation and activation respectively, in secondary
lymphoid organs in mice.
Human Dex harbour functional IL-15Ra and synergize
with IL-15 for NK cell proliferation and IFNc production in
vitro
We next assessed whether human Dex express IL-15Ra
molecules. As shown in Figure 3, IL-15Ra was detected in
immunoblotting of several human Dex preparations purified from
immature DC obtained from normal volunteers (NV) (Fig. 3A).
Other cytokine receptors such as IL-2Ra and IL-7Ra could not be
detected on Dex preparations (data not shown). However, IL-15
was not observed in similar conditions (not shown). In contrast,
tumor-derived exosomes (Tex) harvested in the supernatants of
melanoma cell lines did not bear IL-15Ra molecules (Fig. 3A).
Since Dex harbored IL-15Ra but not IL-15, we next assessed
whether Dex could trans-present exogenous IL-15 to NK cells. As
shown in Figure 3B, autologous Dex (but not Tex) enhanced the
IL-15-driven proliferation of NK cells. As IL-15/IL-15Ra present
on DC induced NK cell activation [51], we studied the activation
status of NK cells stimulated with Dex and/or rhIL-15. Dex as
well as rhIL-15 alone could induce CD69 expression on NK cells
(Fig. 3C). When rhIL-15 and Dex were combined, only an
additive effect could be observed regarding CD69 expression on
NK cells (Fig. 3C). On the other hand, no production of IFNc
could be measured when NK cells were stimulated by Dex alone.
However, the combination of Dex with rhIL-15 could significantly
enhance IFNc secretion by NK cells (Fig. 3D) indicating that Dex
and rhIL-15 could synergize to induce IFNc production by NK
cells in vitro.
These data highlight that IL-15Ra harbored by Dex is
functional, leading to NK cell proliferation and activation in vitro
when associated with rhIL-15.
Dex Induce NK Cell Activation
PLoS ONE | www.plosone.org 2 March 2009 | Volume 4 | Issue 3 | e4942Human Dex bear NKG2D ligands leading to engagement
of NKG2D receptors
In mouse models, Dex induced NK cell activation in an
NKG2D-dependent manner. Next, we evaluated the presence of
NKG2D ligands (NKG2D-L) on human Dex by immunoblotting
and flow cytometry. Western blot analyses revealed the presence of
ULBP-1, one of the NKG2D-L, in Dex preparations obtained
from normal volunteers (Fig. 4A). ULBP-1 was also detected in
DC lysates. However, MICB present in DC was not identified in
Dex (Fig. 4A). We could systematically detect ULBP-1 in normal
volunteers’ Dex preparations whereas no MICA/B could be found
in 6 independent experiments. To rule out any possible
contaminants, we performed extensive purification of Dex on a
continuous sucrose density gradient and confirmed the presence of
ULBP-1 at density gradient corresponding to Dex floatation i.e.
1.16 to 1.19 g/ml (Fig. 4B). Flow cytometry analyses on Dex
coupled to microbeads confirmed the presence of NKG2D ligands
at the surface of Dex (Fig. 4C). In contrast, iDC failed to expose
cell surface NKG2D-L (Fig. 4C). Following coculture of purified
NK cells with autologous Dex, NK cells could i) up-regulate CD69
and HLA-DR (Fig. 3C and not shown) and ii) selectively
downregulate their surface expression of NKG2D receptors
Figure 1. Mouse Dex promoted NK cell proliferation: a role for IL-15Ra.A .Dex induce NK cell influx in draining lymph nodes. Enumeration of
CD3
2 NK1.1
+ cells (NK cells) in the draining lymph node following intradermal inoculation of 10 mg of mouse Dex, or 3610
5 immature DC (iDC), or
10 mg of irrelevant pelleted proteins (cell debris) or PBS. B. NK cells enter cell cycle following Dex inoculation. Proportion of BrdU
+ CD3
2 NK1.1
+ cells
(NK cells) (left panel) or BrdU
+ CD3
+ NK1.1
2 cells (T cells) (right panel) in the draining lymph node following intradermal inoculation of 10 mg of PBS or
mouse Dex in the presence of anti-IL-15Ra blocking mAb (aIL-15Ra) or isotype control mAb (Isotype). The graphs depict the means of absolute
numbers or percentages6SEM of the data from 4 pooled experiments.* p,0.05, ** p,0.01 and ns: ‘‘non significant’’.
doi:10.1371/journal.pone.0004942.g001
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functional. Indeed, the levels of NKp46 remained stable on NK
cells exposed to Dex (not shown). These two effects could be
prevented by pre-incubation of Dex with recombinant NKG2D-
Fc fusion proteins that block the interaction of NKG2D receptors
with their ligands (Fig. 4E).
Altogether, as for mouse Dex, human Dex can activate NK cells
through a NKG2D-dependent mechanism.
Dex vaccination restored numbers and NKG2D-
dependent functions of NK cells in advanced melanoma
patients
We have previously reported the feasability and safety of
vaccination with Dex pulsed with MAGE3.A1 and MAGE3.DP04
peptides in 15 HLA-A1/B35+ and DP04+ stage IIIb and IV
melanoma patients [42]. In this phase I trial, CD4
+ or CD8
+ T cell
responses specific for the vaccinating peptides could not be
detected [42]. Because Dex could induce tumor regressions in 4
melanoma patients but could not elicit T cell activation directed
neither against the vaccinating epitopes nor against autologous
tumor cells [42], we postulated that NK cells could account for
tumor shrinking.
Dex obtained from patients also harboured NKG2D-L as shown
in immunoblotting (Fig. 5A). Contrary to NV Dex, patients’ Dex
express MICA/B and not ULBP1 (Fig. 5A). Although NKG2D
ligands on Dex were different between NV and melanoma patients,
we could not observe any functional consequences regarding
NKG2D-dependent NK cell activation in vitro (data not shown).
Fifteen patients received 4 vaccines at weekly intervals and were
assessed for T and NK cell functions before (W1) and 7 weeks (W7)
after the first Dex inoculation. While the lymphocyte pool remained
Figure 2. Mouse Dex promoted NK cell activation: a role for NKG2D. A. Dex induced NK cell activation in the draining lymph node. Absolute
numbers of CD3
2 NK1.1
+ CD69
+ cells in the draining lymph node following inoculation of 10 mg of mouse Dex, or 3610
5 iDC or 10 mg of irrelevant
pelleted proteins (cell debris) or PBS. Each dot represents the result in one mouse. B. Dex stimulated splenic NK cytotoxicity. Killing assays on
splenocytes against YAC-1 targets at 200:1 and 50:1 (not shown) after intradermal inoculations of 10 mg of Dex every other week for 8 weeks and
sacrifice 48 hrs after the last immunization, or 24 hrs after a single subcutaneous injection of 10 mg of CpG ODN. C. Therapy with unpulsed Dex
reduced number of metastases. Intradermal inoculation of 20 mg of exosomal proteins or PBS 5 days after intravenous injection of 3.10
5 B16F10 tumor
cells. Depletion of NK cells was achieved using 3 administrations of anti-NK1.1 mAbs or isotype control mAbs. Mice were sacrificed on day 10 for
enumeration of lung metastases. D. A role for NKG2D in Dex-mediated NK cell triggering. Enumeration of CD3
2NK1.1
+ cells (left panel) and CD3
2
NK1.1
+CD69
+ cells (right panel) in the draining lymph node following intradermal inoculation of PBS or 10 mg of mouse Dex in the presence of anti-
NKG2D blocking mAb (aNKG2D) or control isotype mAb. The graphs depict the data of 4 pooled experiments (2 for B.). Means and SEM are shown. *
p,0.05, ** p,0.01, *** p,0.001 and ns: ‘‘non significant’’.
doi:10.1371/journal.pone.0004942.g002
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number of circulating CD3
2/CD56
+ NK cells/mm
3 significantly
increased after 4 weekly vaccinations with Dex (Fig. 5B). The study
of the NK cell phenotype in these advanced melanoma patients
revealed that the levels of NKG2D were profoundly decreased
compared with normal volunteerspriortoDexvaccination(Fig.5C)
(36622%) but significantly rose (p=0.011) after 4 injections of Dex
vaccines to 61628% (Fig. 5C). To assess the functional relevance of
this observation, we tested the killing activity of blood NK cells
against K562, a NKG2D ligand-expressing target (Fig. 4C), before
and after Dex therapy in the two cohorts of patients i.e. those who
normalized their NKG2D expression levels and those who did not
(Fig. 5C). Seven out of 14 patients recovered expression levels of
NKG2D $70% after 4 Dex vaccines. Among these responders, the
depressed K562-specific cytotoxicity reverted back to normal levels
after Dex inoculation (Fig. 5C, upper panel). However, non-
responders (i.e. patients in whom Dex did not restore NKG2D
expression) exhibited comparatively low killing activity against
K562 (Fig. 5C, lower panel). In two patients exhibiting tumor
regression (pt#3, pt#12) and continuing on treatment (Dex
administration every other three weeks for 6–10 months), the NK
cell effector functions remained boosted at later time points (W30)
(data not shown). Interestingly, Dex therapy could also up-regulates
NKG2D expression on CD8
+ T cells in 6/14 patients tested (data
not shown).
These data support the notion that Dex inoculation in patients
enhanced the proportion and absolute number of circulating NK
cells and restored NKG2D expression levels on circulating T and
NK cells, thus stimulating the MHC unrestricted NKG2D-
dependent cytotoxicity.
Figure 3. Human Dex harbour functional IL-15Ra and synergize with IL-15 for NK cell proliferation in vitro and IFNc production in
vitro. A. Immunoblotting of IL-15Ra from Dex and DC lysates. Western Blot analysis on 10–40 mg of protein lysates obtained from immature DC (iDC),
Dex or Tex (exosomes from Mel888 melanoma cell line) using anti-IL-15Ra mAb. Positive controls included anti-HLA-DRa, -TSG 101 and -HSC 70 Abs.
Representative immunoblots of two normal volunteers are depicted (NV1 and NV2). Molecular weights are indicated on the left lane. B. Proliferative
effects of recombinant IL-15 and Dex on NK cells. CFSE-labeled NK cells were cultured with or without 10 mg autologous Dex or allogenic Tex in
complete medium containing 0.5 ng/ml of human recombinant IL-15. At day 6 of culture, NK cell proliferation was determined by flow cytometry and
the number of divisions were counted and depicted. A representative experiment out of two is shown. C–D. Synergistic effects between Dex and
recombinant IL-15 for NK cell triggering. NV’s PBL were cultured without (white histograms) or with (black histograms) 10 mg autologous Dex and
increasing concentrations of human recombinant IL-15. NK (CD56
+ CD3
2) cells were then analysed for CD69 expression by flow cytometry (C) or
supernatants were harvested to measure IFNc levels in EIA (D). The graphs depict means6SEM of % of CD69 expressing NK cells in 3 experiments (C)
or IFNc concentrations in 4 experiments (D). * p,0.05, ** p,0.01 and ns: non significant.
doi:10.1371/journal.pone.0004942.g003
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PLoS ONE | www.plosone.org 5 March 2009 | Volume 4 | Issue 3 | e4942Figure 4. Human Dex harbour functional NKG2D ligands. A–B. Immunoblot detection of NKG2D ligands on Dex. (A) 10–40 mg of protein lysates
from immature DC (iDC), Dex or tumor cells (K562, GIST) were assayed in western blot analyses using anti-ULBP-1 and MICB Abs on whole protein
lysates (A) (this result was similar in 6 Dex preparations from 6 different healthy donors) or on each fraction of distinct density (B) following
ultracentrifugation of 400 mg of Dex proteins on a continuous density gradient. Controls included anti-HLA-DRa, TSG 101, hsc 70 Abs and anti-c
tubulin Abs are also depicted. Molecular weights are indicated on the left lane. Note that the density of the ULBP-1 positive Dex fractions is
approximately 1.16 to 1.19 g/ml i.e. the assumed density flotation of Dex. C. Dex express cell surface NKG2D ligands. Flow cytometry analyses of the
surface expression of NKG2D ligands (empty histograms) on beads coated-Dex using rhNKG2D-Fc chimera or a mix of anti-human MICA/B, ULBP-1,
ULBP-2 and ULBP-3 mAbs and appropriate secondary Abs. Similar stainings of iDC and K562 cells (a negative and positive control respectively). Filled
histograms represent stainings with isotype matched mAbs. D. Engagement of NKG2D receptors on NK cells triggered by Dex. NK cells were incubated
40 hrs with medium or 10 mg autologous Dex or irrelevant pelleted proteins (cell debris) coated onto MaxiSorp
TM wells, and then stained with anti-
CD3 APC, anti-CD56 CyC, anti-NKG2D PE mAb. Flow cytometry analyses revealed the mean % (6SEM) of NKG2D expressing NK cells in three
independent experiments performed in triplicate wells. E. NKG2D-dependent NK cell activation by Dex in vitro. Identical setting as in D. but using
rhNKG2D-Fc fusion proteins or Ig-Fc controls to determine CD69 (left panel) and NKG2D (right panel) expression on NK cells in flow cytometry
analyses. * p,0.05.
doi:10.1371/journal.pone.0004942.g004
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Here, we provide the first evidence that GMP manufactured
dendritic cell-derived exosomes can trigger NK cell proliferation
and activation in vitro and in patients. Although other reports
claimed that exosomes harboring the nuclear factor BAT3 [52]
(NKp30-interacting partner) or HSP70 derived-peptides [53,54]
could induce NK cell triggering, our data focusing on DC derived-
exosomes in mice and humans demonstrate a critical role for IL-
15Ra-and NKG2D for Dex-mediated NK cell proliferation and
activation respectively.
Designing of DC vaccines inducing an efficient NK cell
response could aid the establishment of Th1 polarization of
cognate immune responses. However, NK cell activation in
vaccination protocols has been rarely studied [32]. Ex vivo
protocols generating DC capable of secreting high levels of IL-
12 (TLR3 ligands and type 1 IFN or CD40L/agonistic CD40
mAb, IFNc, IL-1b containing regimen, ex vivo licensing by
activated NK cells) are currently developed [55,56]. Osada and
colleagues were the first to monitor NK cell responses in tumor
patients vaccinated with DC. They showed that NK cell responses
following DC vaccination may correlate more closely with clinical
outcome than do T cell responses [55]. Other cell-free vaccines
containing heat shock proteins derived from melanoma or colon
tumors could induce NK cell activation in patients and may
contribute to the priming of T cell responses and/or tumor
shrinking [57]. In our clinical trial aimed at vaccinating with Dex
melanoma patients, we have been able to show that Dex boosted
recirculation of NK cells and restored NKG2D expression and
function on NK cells.
Upon binding to its ligand, NKG2D stimulates the NK cell lytic
pathway, resulting in killing of transformed or altered cells.
NKG2D engagement induced the secretion of cytokines such as
IFNc and GM-CSF [58]. However, Oppenheim et al. have
demonstrated that long term exposure to NKG2D ligands resulted
in impaired natural cytotoxicity in vivo and reduced tumor
immunosurveillance [59]. Indeed, NK or CD8
+ T cells from
cancer patients often exhibit a profound downregulation of the
expression of NKG2D receptors. The NKG2D downregulation in
cancer patients has been correlated with high levels of circulating
MICA/B molecules shed by the tumor burden [60], or with
circulating mature TGF-b or to regulatory T cells expressing
membrane bound TGF-b [60–62]. We were not able to detect
significant concentrations of plasma TGF-b or serum MICA/B in
our 14 melanoma patients that could account for the low
expression of NKG2D receptors (not shown). Here we describe
a novel form of shed NKG2D ligands which is membrane bound
and harbored by Dex. Indeed, Dex convey functional NKG2D
ligands both in mice and humans leading to NK cell triggering.
This phenomenon contrasts with shed NKG2D ligands that are
inhibitory [59].
Different teams have reported that tumor-derived exosomes
(Tex) could modulate NK cell activity. In vitro, Tex have been
described to enhance NK cell function through Heat Shock
Protein 70 (Hsp70) surface expression [53]. These Hsp70 positive
Tex have been shown to synergize with NKG2D ligands expressed
on the tumor cell surface resulting in reduction of tumor growth
and suppression of metastatic disease [54]. However, Liu and
colleagues have suggested that Tex could inhibit NK cells through
the blockade of IL-2 mediated NK cell activation leading to tumor
escape [63]. Finally, Clayton and colleagues have shown that Tex
could harbor MICB molecules leading to down regulation of
NKG2D on peripheral blood lymphocytes in vitro (CD8
+ T cells
and CD3
+CD8
2 T cells) [64]. This diminution of NKG2D
expression on CD8
+ T cells was associated with an inhibition of T
cell cytotoxicity in vitro. Consequently, authors claimed that
NKG2D expression on Tex could be another mechanism of
tumor invasion [64]. More recently the same team described that
Tex-induced NKG2D down-modulation was partially due to
NKG2D ligands expressed on Tex [65]. In contrast they clearly
showed that this effect was the consequence of TGF-b1 carried by
Tex [65]. For Dex few works have shown their capacity to activate
NK cells in vitro [52]. In our study dealing with Dex, we clearly
show that Dex could engage NKG2D on NK cells in vitro,a
signaling cascade that might synergize with IL-15Ra triggering.
Moreover our data provide for the first time the demonstration
that the level of NKG2D expression on NK cells (Fig. 5) and CD8
+
T cells (not shown) are increased after 4 vaccinations with Dex in
humans. Indeed, the presence of other receptors such as IL-15Ra
may contribute to restore the level of NKG2D expression on NK
and CD8
+ T cells allowing restoration of these lymphocyte
functions at least ex vivo (Fig. 5C and not shown). This observation
demonstrates that the composition of exosomes is critical for NK
cell activation since Tex that do not harbor IL-15Ra (Fig. 3A)
failed to do so. Consequently in association with recombinant IL-
15 Dex were able to boost IFNc secretion (Fig. 3D). In contrast,
Tex can decrease effector function of NK cells. IL-15, a
recognized potent positive modulator of NKG2D-dependent
responses of NK cells is rendered poorly activating in the presence
of Tex [65]. This observation that exosomal NKG2D ligands
release can lead to NK activation highlight a novel mechanism of
NKG2D dependent NK cell triggering. Indeed, while exosomal
forms of NKG2D ligands seem to activate NK cells, the release of
soluble forms that are mediated through shedding activity inhibits
NK cell functions.
Trans-presentation of IL-15 as been described to have a pivotal
role in NK cell homeostasis, survival and proliferation [46,66,67].
Moreover, it can enhance and restore NKG2D expression and
function [68]. Dex harbored functional IL-15Ra (Fig. 3) but
lacked IL-15 (data not shown). Since IL-15 is produced by a vast
diversity of cells in vivo, we can postulate that endogenous IL-15 is
presented by IL-15Ra harbored by Dex leading to significant NK
Figure 5. Vaccination of melanoma patients with Dex restored NKG2D-dependent NK cell function. A. Patients’ Dex harbour MICA/B
molecules. Western Blot immunodetection of NKG2D-L using anti-MICA/B and anti- ULBP-1 Abs (not detected) on 40 mg of Dex proteins. B. Dex
enhanced the numbers of circulating NK cells in melanoma patients. Enumeration of lymphocytes (left panel) and flow cytometry determination of the
percentages (middle panel) and absolute numbers (right panel) of CD3
2 CD56
+NK cells in PBMC prior to (W0) and following Dex vaccination (W7) in
the Phase I trial enrolling 14 melanoma patients. C. Restoration of NKG2D expression and function by Dex therapy in melanoma. Flow cytometry
analyses of NK cells using anti-NKG2D or isotype matched control mAb, anti-CD3, and anti-CD56 mAbs were performed on PBL of normal volunteers
(NV) or of patients before Dex therapy (W0) and after Dex therapy (W7). Purified autologous NK cells from 14 patients enrolled in the Phase I trial at
W1 or W7 or from 10 NV were investigated for cytotoxic activity against
51Cr labeled K562 cells at a 10:1 (shown) and 2:1 (not shown) E:K562 ratio.
Two tests per individual were run yielding identical results. Intra-individual variations were ,10%. Means6SD for 10 normal volunteers (NV), for 14
melanoma patients before Dex therapy (W0) and after Dex therapy (W7) are represented. The upper panel depicts the NK cell cytotoxicity when
NKG2D expression levels were restored at W7 (.70%) in contrast to the lower panel indicating the NK cell cytotoxicity in patients whose NKG2D
expression remained low (,70%). * p,0.05 and ns: non significant.
doi:10.1371/journal.pone.0004942.g005
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restoration in melanoma patients (Fig. 5). A recent work showed
that in vivo delivery of IL-15/IL-15Ra complexes triggers rapid
and significant regression of established solid tumors in two murine
models [69]. These data provide novel insights into the use of IL-
15/IL-15Ra complexes to relieve tumor-resident immune cells
from functional suppression by the tumor microenvironment and
have significant implications for cancer immunotherapy [69].
Dubois and coll. also demonstrated that mimicking IL-15 trans-
presentation strongly increased the IL-15-mediated proliferation of
murine NK and CD8
+/CD44
high T cells. When mice bearing the
NK-sensitive syngeneic tumor B16 were treated, the presence of
IL-15Ra-IgG1-Fc increased the anti-tumor activity of IL-15 [70].
Thus, Dex could represent a new tool for IL-15 trans-presentation
in vivo.
Dex express both IL-15Ra and NKG2D ligands that can
synergize to induce NK cell triggering. Therefore, Dex could
represent a link between innate and antigen specific T cell
responses that could participate in tumor regression [33,71]. We
indeed showed that in the absence of Treg [72] or in the
presence of TLR agonists [41], Dex could trigger tumor antigen-
specific CD8
+ T cell responses leading to tumor regression [73].
Knowing that NK cell recruitment/proliferation and activation
play a key role in promoting Th1 differentiation [71], Dex could
represent a suitable vaccine that could activate in unison innate
and adaptive immunity. Engineering Dex with increased
expression of both IL-15Ra and NKG2D ligands could lead to
a significant enhancement of anti-tumor responses in vivo.
Different works have demonstrated that the maturation stage
of DC that produce Dex have a critical impact on the Dex
composition leading to a better capacity to activate T and NK
cells [52,74–76]. In our lab, our preliminary unpublished data
demonstrate that Dex produced from IFNc-treated DC are
enriched with NKG2D ligands and IL-15Ra.T h i so b s e r v a t i o n
remains to be confirmed and the functional relevance of this
phenomenon has to be demonstrated. In consequence, we are
currently, in Gustave Roussy Institute, launching a phase II
clinical trial in which metronomic dosage of cyclophosphamide
followed by Dex vaccination (these Dex are produced from
mature DC and harbor IL-15Ra and NKG2D ligands) are
evaluated for the treatment of inoperable patients bearing stage
IIIB/IV non-small cell lung cancer who responded or experi-
enced disease stabilization after the first line chemotherapy.
During this clinical trial, we will monitor both immune functions
in vaccinated patients and Dex phenotype to determine if the
regulation of the specific sorting of NKG2D-L in Dex appears to
be also different between NV and non-small cell lung cancer
patients. We hope to reinforce the postulate that NK cell
together with T cell responses might cooperate to correlate with
clinical responses.
Materials and Methods
Protocol design, patients’ characteristics and eligibility
criteria
The study was approved by the Kremlin Bice ˆtre Hospital
Ethics Committee (Comite ´ de Protection des Personnes) and
regulatory authorities, and informed written consent was obtained
from each patient. Fifteen patients bearing melanoma fulfilling the
inclusion criteria were enrolled in the study. Patients received a 4
week vaccination course with antigen loaded Dendritic cell-
derived exosomes (Dex) given intradermal and subcutaneous
injections every week for a total of 4 vaccinations as already
described [42].
Mice
Female C57BL/6 (H-2
b) wild type (BL6) were obtained from
the ‘‘Centre d’ Elevage Janvier’’ (Le Genest St Isle, France), and
maintained in IGR animal facilities according to the Animal
Experimental Ethics Committee Guidelines.
DC culture
Mouse bone marrow derived-DC (BM-DC) were cultured as
previously described [41]. Briefly, bone marrow progenitor cells
were grown in IMDM culture medium (Sigma-Aldrich, France)
supplemented with 50 U/ml penicillin, 50 mg/ml streptomycin,
2 mM L-glutamine, 10% decomplemented fetal calf serum
(Gibco-BRL, France), 50 mM 2-ME (Sigma-Aldrich) and 30%
J558-mGM-CSF culture supernatants for 10–12 days. Human
monocyte-derived DC (MD-DC) were generated from normal
volunteers’ monocytes purified after elutriation of peripheral blood
according to the French EFS procedures (Pr J. Bernard, Institut
Jean Godinot, Reims, France). MD-DC were cultured in bags
under adherence-free conditions (Lifecell, Baxter) for 5 days in
serum-free AIMV medium (Gibco-BRL) supplemented with
1000 UI/ml of rhGM-CSF (R&D Systems) and 200 UI/ml of
rhIL-4 (Schering Plough). Patients’ monocyte-derived DC (MD-
DC) were obtained according to a good manufacturing process
already described [77]. MD-DC were generated from the
adherent fraction of peripheral blood mononuclear cells (PBMC)
in AIM-V medium (Gibco-BRL) supplemented with 1000 IU/ml
of rhu GM-CSF (Leucomax, Schering-Plough, Levallois-Perret,
France) and 1000 IU/ml of rhu IL-4 (Schering Plough, Kenils-
worth, NJ) as previously described [78].
Exosome production and purification from mice and
human DC
Mouse Dex were manufactured using the same procedure as
that described for the MELADEX clinical trial [77]. For exosome
production, cells were cultured for 48 h to 72 h in complete
medium depleted from FCS-derived exosomes by diafiltration.
Exosomes were isolated following a process of ultrafiltration/
diafiltration described by Lamparski and colleagues [77]. The
supernatant of the resulting dendritic cell preparation was
harvested, filtered, subjected to serial centrifugation to remove
cells and debris, and ultrafiltered through a 500-kDa filter. This
preparation was underlaid with 30% sucrose/D2O and ultracen-
trifuged at 100,0006g. The cushion containing exosomes was
diafiltrated to remove the sucrose. Exosomes were pelleted by
ultracentrifugation at 100,0006g, resuspended in PBS and stored
at 280uC. In patients, exosomes were purified from MD-DC
culture supernatants according to a good manufacturing process
already described [42,77].
Sucrose gradient
Purified exosomes were resuspended in 2 ml of Hepes 20 mM /
Sucrose 2.5 M and floated into an overlaid linear sucrose gradient
(2–0.25 M) in a SW41 tube for 16 hrs at 100,0006g. Gradient
fractions of 1 ml were collected from top to bottom and analysed
by SDS-PAGE and immunoblotting.
In vivo assays in mice
Determination of NK cell number in LN. Increasing
amounts of Dex (up to 10 mg) and graduated numbers of
immature DC (up to 3.10
5 iDC) or 10 mg of irrelevant pelleted
proteins were inoculated in one footpad of BL6 mice. Popliteal
ipsi- and contro-lateral nodes (PBS injected) were harvested at
36 hrs. In neutralizing experiments, Dex were inoculated in
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San Diego, USA) or anti-mouse IL-15Ra (R&D Systems)
neutralizing mAbs or with the corresponding isotype Ab. Lymph
node mononuclear cells were mechanically minced. Cells were
enumerated using trypan blue exclusion prior to immunostaining
with three color mAbs anti-CD3 FITC, anti-NK1.1 APC and anti-
CD69 PE (BD Pharmingen). BrdU incorporation. For BrdU
incorporation assays, 1.5 mg of BrdU solution was injected per
mice i.p. the day of Dex inoculation. The day after, lymph node
NK or T cells were analyzed in flow cytometry using NK1.1/CD3
staining. BrdU incorporation was revealed using APC anti-BrdU
antibody according to BrdU Flow kit (BD Pharmingen) and
analyzed by flow cytometry (FACSCalibur, BD). Assessment of
NK cell cytotoxic activity. Twenty mg of Dex or 20 ml of PBS
were inoculated each week for 8 weeks or 10 mg ODN CpG 24 hrs
before sacrifice (provided by Dr. A. Carpentier, AP-HP Pitie ´
Salpe ´trie `re, Paris, France) were injected intradermally in BL6
mice. Spleens were mechanically minced. Cells were enumerated
using trypan blue and used as effector cells. Cytotoxicity of
splenocytes was measured in a standard 4 hrs
51Cr-release assay
using Na2
51CrO4-labeled YAC-1 targets. Experiments were
conducted in triplicates at various E:T ratios (200:1 and 50:1).
Antitumor experiments. 3.10
5 B16F10 tumor cells were
inoculated in the tail vein at day 0, Dex or controls were injected
at day 5 and mice were sacrificed at day 10 for the enumeration of
lung metastases. NK cell depletion was achieved using i.p.
injections of 300 mg of anti-NK1.1 mAb (PK136) or isotype
control Ab at day-4, day0 and day+4 as described elsewhere [79].
Assessment of NK cell activity in normal volunteers
In vitro proliferation experiments. Ten mg of Dex were
coated onto sterile MaxiSorp
TM plate (Nunc) at 4uC during
18 hrs. The next day, autologous purified NK cells and 0.5 or
5 ng/ml of rhIL-15 (R&D Systems) in AIMV medium (Gibco-
BRL) were added. Human NK cells were purified from frozen
elutriated peripheral blood lymphocytes (PBL) with EasySep
TM
human NK cell enrichment kit (StemCell Technologies, Vancou-
ver) and labelled with 2.5 mM CFSE (Sigma-Aldrich). At day 6 of
coculture, half of the medium was replaced with fresh medium
supplemented with cytokine. Cells were collected at day 6 and 14
and analysed for proliferation by flow cytometry. NK cell
activation assay. PBL were cocultured with 10 mg autologous
Dex bound onto MaxiSorp
TM plate for 2 days. IFNc secretion was
measured with BD OptEIA kit in the supernatants. Cells were
harvested and stained for flow cytometry analysis with anti-CD3
FITC, anti-CD69 PE (BD Pharmingen) and anti-CD56 APC
mAbs (Beckman Coulter) or anti-CD3 APC, anti-CD69 FITC (BD
Pharmingen), anti-CD56 CyC (Beckman Coulter) and anti-
NKG2D PE (R&D Systems) mAbs. In blocking experiments,
Dex were pre-incubated or not with rhNKG2D-Fc chimera (R&D
Systems) or human Ig-Fc chimera control (Alexis Biochemical).
Assessment of NK cell activity in patients
PBMC were isolated by Ficoll density centrifugation (Ficoll-
Paque
TM, Amersham Pharmacia Biotech AB, Uppsala, Sweden)
from leukaphereses performed before (W1) and after Dex vaccines
(W7) according to the institutional guidelines. Cells were
enumerated using trypan blue exclusion test. Cells were analysed
by flow cytometry using anti-CD45, CD3 and CD56 mAbs for
determination of total lymphocytes and NK cells numbers and NK
cells percentages. Purified (85–90% CD3
2/CD56
+) NK cells were
obtained from PBL of W1, W7 and W30 using EasySep
TM human
NK cell enrichment kit (StemCell Technologies, Vancouver). NK
cells prior to (W1) or following Dex vaccines (W7 and W30) were
tested in Na2
51CrO4 chromium release assays against K562 cells
after 40 hrs stimulation with AIMV culture medium alone in 96 U
bottom well plates. Experiments were conducted in triplicates at
various E:T ratios. For the determination of NKG2D expression
on NK cells before (W1) and after Dex therapy (W7), cells were
analysed by flow cytometry using mouse anti-NKG2D PE (R&D
Systems), anti-CD56 CyC (Beckman Coulter), and anti-CD3 APC
mAbs (BD Pharmingen).
Immunoblotting
Cells or exosomal proteins were extracted in lysis buffer (50 mM
Tris-HCl, pH 7.5, 250 mM NaCl, 0.1% NP-40, 10 mM
Na3VO4, 5 mM DTT, protease inhibitor cocktail tablet (Com-
plete, Mini, EDTA-free, Roche)) for 30 min at 4uC. Nuclei and
cell debris were removed by centrifugation. Proteins in lysates
were quantified by DC
TMProtein Assay (Bio-Rad Laboratories).
Aliquots of protein extracts were solubilised in Laemmli loading
buffer and resolved by 10% SDS-PAGE and transferred onto
nitrocellulose or PVDF membranes (Bio-Rad Laboratories).
Membranes were saturated for 1 hr and incubated with primary
Abs for 1 hr at room temperature or over night at 4uC. Primary
Abs were probed with the appropriated horseradish peroxidase-
labelled secondary Abs (Southern Biotech) and detected by
SuperSignal West Pico Chemiluminescent Substrate (Pierce).
Primary Abs included: anti-IL15Ra, anti-ULBP-1, anti-MICB
(R&D Systems), anti-TSG101, anti-MICA/B C-19 (Santa Cruz
Biotechnology), anti-hsc 70 (Stressgen), anti-c Tubulin (Sigma-
Aldrich) and anti-HLA-DRa (kindly provided by P. Benaroche,
Institut Curie, France).
Exosome surface analysis
Purified exosomes were coupled to 4 mm aldehyde / sulphate
latex beads (Molecular Probes) as described elsewhere [77] and
immunostained. Abs included mouse isotype controls or human
Ig-Fc chimera as a negative control for Fc chimeric protein (Alexis
Biochemicals), mouse anti-human MICA/B, ULBP-1, ULBP-2
and ULBP-3 or rhNKG2D-Fc chimera (R&D Systems), and
FITC-conjugated goat anti-mouse IgG Fc (Jackson ImmunoR-
esearch) or PE-conjugated goat anti-human IgG Fc (Rockland).
To confirm exosome binding to beads, anti-CD63 PE, anti-CD81
PE (BD Pharmingen) and anti-CD82 PE (Diaclone) mAbs were
used as a control. Human DC and K562 cells were used
respectively as a negative and a positive control of the NKG2D
ligands staining. The exosome-bead complexes and cells were
analysed on a FACSCalibur flow cytometer with the FlowJo
analysis software.
Statistical analyses
All results are expressed as means6standard error of the mean
(SEM) or as ranges when appropriate. For two groups, normal
distributions were compared by the unpaired or paired Student’s t
test when appropriate; non-normal samplings were compared
using the Mann-Whitney’s test or Wilcoxon matched paired test
when appropriate. For more than two groups, analyses of
variances were performed with the Kruskal-Wallis test. Statistical
analyses were performed using Prism 5 software (GraphPad, San
Diego, CA). P values of ,0.05 were considered significant.
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